Gary, imo I agree that dcvax-l could eventually get to a billion per year in sales. However I believe it will take some time and additional trials for additional indications.
Assuming it is approved in the UK for gbm and price is $200,000 (assuming NICE agrees to this price) it will have a hard time reaching such sales. I think there are 3,000 cases of gbm in the UK each year, assuming 100% market penetration this give sales at 600 million. There should of course be revenues for rGBM but most do not survive long. If they can next get EU approval then such revenue could be achieved. I just think it will be a few years to achieve this level of revenues.
Hopefully initial approval will lead to additional trials and indications
Market Data 
Markets 
AI
